Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you use a hormonal implant and are considering Mounjaro for weight management, the reassuring answer is that the implant is not expected to be affected by tirzepatide. Unlike oral contraceptives, the implant releases progestogen directly into the bloodstream rather than through the gut, so the fact that Mounjaro slows gastric emptying is not relevant to how well it works. That said, the full picture involves a few practical points worth understanding before you start treatment, and a prescriber will always discuss your contraception at consultation. Mounjaro is a prescription-only medicine requiring a clinical assessment before it can be supplied.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The core concern with Mounjaro and hormonal contraception centres on absorption. Tirzepatide slows the rate at which the stomach empties, which can reduce how quickly and completely oral medicines (including the combined or progestogen-only pill) are absorbed. That is why NHS guidance on Mounjaro and hormonal contraception singles out oral contraceptives specifically, advising that a non-oral backup method is used for the first four weeks of treatment and for four weeks after any dose increase.
The implant sidesteps this mechanism completely. It is a small flexible rod inserted under the skin of the upper arm, releasing a steady low level of progestogen directly into your bloodstream. There is no gut absorption step. Mounjaro cannot interrupt a process that does not happen. On that basis, the implant is considered unaffected by tirzepatide under current UK clinical guidance.
This distinction matters practically. If you switched to the pill before starting Mounjaro, the pill-specific precaution would apply to you. If you keep the implant, it does not. Worth knowing before you make any contraceptive changes.
The NHS England guidance on weight-management injections is explicit that women using oral contraceptives should add a barrier method for the first four weeks of Mounjaro and after each dose step up. It does not flag the same requirement for non-oral hormonal methods, including the implant, the patch, the hormonal coil or injectable contraceptives.
The Mounjaro SmPC (the authoritative prescribing document) notes the gastric-emptying effect on co-administered oral medicines and specifically names oral contraceptives as requiring backup. The implant is not listed as a concern, and if you are curious whether tirzepatide acts as a stimulant or works through some other mechanism, that is covered separately. You can read the full prescribing information via the eMC, which holds the Mounjaro Summary of Product Characteristics.
One honest caveat: the long-term effects of significant weight loss on hormonal levels and contraceptive effectiveness are still being studied across all methods. This is not a Mounjaro-specific concern (rapid body composition changes can affect hormone binding and metabolism) but it is a reason to keep your GP and prescriber informed about your progress rather than treating the question as settled once and done.
Most people reading this are weighing up whether they need to do anything about their contraception before starting Mounjaro. The straightforward answer is: if your only hormonal contraceptive is the implant, current guidance does not require you to add a backup method. That is meaningfully different from the position for pill users.
If you use the pill alongside the implant, the pill precaution applies to you. If you are thinking about changing your contraception (moving from the implant to the pill, say, because your implant is due for replacement) timing that change relative to starting Mounjaro is worth discussing with whoever manages your contraception as well as your Mounjaro prescriber.
Mounjaro treatment is reviewed before every repeat at nume. You can see what that process involves on our Mounjaro treatment plan page, and our clinical team's approach to situations like this is set out on our clinical team profile. A quick look at what Mounjaro costs privately is also useful background if you are still deciding whether to proceed.
Mounjaro is not recommended during pregnancy, while breastfeeding, or in the period when you are actively trying to conceive. The MHRA and SmPC guidance is that effective contraception should be used throughout treatment and for a wash-out period afterwards, your prescriber will advise on the specific timeframe at consultation, because it varies based on your dosing history.
If you are approaching the end of your implant's three-year lifespan and you are thinking about trying for a baby, that timing conversation becomes especially important. Do not stop your implant and begin trying to conceive without first speaking to your prescriber about when to stop Mounjaro. The wash-out period exists for a reason, and planning it properly is straightforward when you raise it early.
If any of this raises questions specific to your situation, speaking to our prescribers is the right next step. Consultations at nume are free, reviewed the same day by a named clinician, and there is no obligation to proceed. For broader context on how Mounjaro works as a treatment, the Mounjaro overview is a good place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.